RG
PRQR icon

Redmile Group’s ProQR Therapeutics PRQR Stock Holding History

Redmile Group’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,450,925
Closed -$28.1M – 86
2018
Q3 		$28.1M Buy
+1,450,925
New +$15.4M 0.86% 43
2018
Q1 		– Sell
-1,558,392
Closed -$5.03M – 72
2017
Q4 		$5.03M Sell
1,558,392
-44,583
-3% -$160K 0.22% 57
2017
Q3 		$7.77M Buy
1,602,975
+6,700
+0.4% +$34.8K 0.38% 48
2017
Q2 		$8.3M Buy
1,596,275
+43,050
+3% +$214K 0.51% 47
2017
Q1 		$7.77M Sell
1,553,225
-24,949
-2% -$110K 0.5% 49
2016
Q4 		$7.73M Buy
1,578,174
+1,002,311
+174% +$5.16M 0.67% 33
2016
Q3 		$3.84M Sell
575,863
-5,775
-1% -$31.8K 0.31% 41
2016
Q2 		$2.81M Buy
581,638
+28,925
+5% +$149K 0.27% 44
2016
Q1 		$2.7M Sell
552,713
-4,480
-0.8% -$22.8K 0.28% 41
2015
Q4 		$4.84M Sell
557,193
-103,623
-16% -$1.19M 0.36% 41
2015
Q3 		$9.63M Buy
660,816
+144,126
+28% +$2.41M 0.73% 33
2015
Q2 		$8.61M Sell
516,690
-234,481
-31% -$4.42M 0.71% 38
2015
Q1 		$16.4M Hold
751,171
– – 1.48% 28
2014
Q4 		$15.7M Sell
751,171
-14,061
-2% -$213K 1.71% 24
2014
Q3 		$12.1M Buy
+765,232
New +$12.3M 1.39% 33

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Redmile Group's PRQR Position: Q4 2018 in Review

Redmile Group sold out of ProQR Therapeutics (PRQR) in Q4 2018, closing a stake of 1,450,925 shares — an estimated $28.1M sold.

Redmile Group first reported a position in PRQR in Q3 2014 and held it in 15 quarters. The position peaked at $28.1M in Q3 2018. 57 funds tracked by Wall St. Rank hold PRQR as of Q4 2018.

  • Redmile Group reported no remaining ProQR Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Redmile Group sold 1,450,925 ProQR Therapeutics shares in Q4 2018, an estimated $28.1M.
  • Redmile Group first reported a position in ProQR Therapeutics in Q3 2014 and held it in 15 quarters.
  • Redmile Group's ProQR Therapeutics position peaked at $28.1M in Q3 2018.
  • 57 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2018.

Based on Redmile Group's 13F filing for Q4 2018, filed 14 Feb 2019.